Legislation would close the loophole in California's pet retail ban by prohibiting brokers from selling or shipping dogs to ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...

Genmab AS (GMAB) reports a 31% revenue increase and outlines strategic plans for 2025 amidst competitive market challenges.

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...

Vertiv is projecting another year of sales growth as the bustling data center market continues to provide it with strong pipeline activity.

Alkermes PLC (ALKS) reports over $1.5 billion in revenue, retires all debt, and outlines strategic plans for 2025 amidst ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Puppy milling, also called puppy farming, is the practice of breeding dogs for profit while disregarding the health and ...

Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...